```
=> d his

     (FILE 'HOME' ENTERED AT 10:57:36 ON 20 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:57:44 ON 20 NOV 2007
L1                SCREEN 1839
L2                SCREEN 1840
L3                STRUCTURE UPLOADED
L4         835823 S SC4/ES
L5              5 S (L3 NOT L2) SAM SUB=L4
L6            159 S (L3 NOT L2) SSS FULL SUB=L4

     FILE 'CAPLUS' ENTERED AT 10:59:53 ON 20 NOV 2007
L7             21 S L6
L8              2 S US200!-537697/APPS
L9              1 S L7 AND L8
L10            20 S L7 NOT L8

     FILE 'REGISTRY' ENTERED AT 11:00:22 ON 20 NOV 2007

=> d l3
L3 HAS NO ANSWERS
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

=> d l9 bib abs

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:515662 CAPLUS
DN 141:47386
TI Ureidothiophene compound NF-κB inhibitor for therapeutic use
IN Callahan, James Frances; Li, Yue Hu
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004053087	A2	20040624	WO 2003-US38970	20031205
	WO 2004053087	A3	20040910		
	W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, EG, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, VN, YU, ZA				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003300832	A1	20040630	AU 2003-300832	20031205
	EP 1569924	A2	20050907	EP 2003-812858	20031205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006510676	T	20060330	JP 2004-559435	20031205
	US 2006116419	A1	20060601	US 2005-537697	20050606 <--
PRAI	US 2002-431496P	P	20021206		
	WO 2003-US38970	W	20031205		

AB The invention provides 5-(4-fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide (preparation described) and methods for treating diseases related to the inhibition of IKK-β phosphorylation of Iκ.

=> d l10 tot bib abs hitstr

L10 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:1060852 CAPLUS Full-text
DN 147:378396
TI nf-kb activation inhibitors for treating muscular wasting diseases
IN Guttridge, Denis C.; Baldwin, Albert S.
PA Theraltrics, Inc., USA
SO PCT Int. Appl., 64pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007106884	A2	20070920	WO 2007-US64057	20070315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007225315	A1	20070927	US 2007-686623	20070315
PRAI US 2006-782427P	P	20060315		

AB Methods for treating muscular wasting diseases such as Duchenne muscular dystrophy are disclosed. Specifically, the methods include administering to a subject in need of treatment a nuclear factor kappa B (NF-KB) activation inhibitor capable of blocking the activation of NF-KB. Administration of peptides comprised of a Nuclear Factor Essential (NEMO) binding domain to a mouse model of Duchenne muscular dystrophy significantly increased diaphragm contractions.
IT 354810-86-9 507475-17-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nf-kb activation inhibitors for treating muscular wasting diseases)
RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 507475-17-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:279958 CAPLUS Full-text
DN 146:493299
TI Inhibition of Aβ production by NF-κB inhibitors
AU Paris, Daniel; Patel, Nikunj; Quadros, Amita; Linan, Monica; Bakshi, Pancham; Ait-Ghezala, Ghania; Mullan, Michael
CS Roskamp Institute, Sarasota, FL, 34243, USA
SO Neuroscience Letters (2007), 415(1), 11-16
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Ltd.
DT Journal
LA English
AB The transcription factor nuclear factor κB (NF-κB) is widely expressed in the nervous system and increased NF-κB immunoreactivity has been observed in Alzheimer's disease (AD) brains in the nuclei of neurons within the vicinity of diffuse β-amyloid plaques. β-Amyloid (Aβ) peptides are the main constituent of senile plaques and are known to stimulate NF-κB activity. In the present study, we investigated the effect of various NF-κB inhibitors on the production of Aβ1-40, Aβ1-42, secreted APP (sAPPβ and sAPPα) and APP C-terminal fragments (APP-CTF) using CHO cells overexpressing the β-amyloid precursor protein (APP). Our data show that NF-κB inhibitors decrease both Aβ1-40 and Aβ1-42 production In addition, we show that some NF-κB inhibitors decrease sAPPβ and APP-CTFβ suggesting that they reduce the β-secretase cleavage of APP. Altogether our data suggest that NF-κB inhibitors may be of therapeutic importance for the treatment of AD pathol. not only by blocking inflammatory processes but also by directly inhibiting the production of Aβ peptides.
IT 507475-17-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of Aβ production by NF-κB inhibitors)
RN 507475-17-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:76699 CAPLUS Full-text
DN 146:115045
TI Treating type 2 diabetes or metabolic syndrome with an interleukin 1β inhibitor or an interleukin 1β synthesis or release inhibitor
PA Novo Nordisk A/S, Den.
SO Dan. Pat. Appl., 16pp.
CODEN: DAXXBG
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DK 2006000313	A	20060313	DK 2006-313	20060303
PRAI DK 2006-313		20060303		

AB The invention describes a method for treating type 2 diabetes or metabolic syndrome with a compound that inhibits (a) IL-1β, (b) the synthesis of IL-1β, or (c) the release of IL-1β.
IT 354810-80-3 354810-83-6 354810-86-9 354810-88-1 354810-95-0 354811-01-1 354811-04-4 354811-06-6 354811-07-7 354811-08-8 354811-09-9 354811-10-2 354811-14-6 354811-15-7 354811-19-1 354811-27-1 354811-28-2 354811-29-3 354811-30-6 354811-31-7 354811-32-8 354811-33-9 354811-34-0 354811-35-1 354811-36-2 354811-37-3 354811-38-4 354811-39-5 354811-40-8 354811-41-9 354811-42-0 354811-48-6 354811-49-7 354811-50-0 354811-52-2 354811-54-4 354811-56-6 354811-58-8 354811-59-9 354811-60-2 354811-66-8 354811-67-9 354811-68-0 354811-92-8 354811-93-9 918475-53-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin 1β inhibitor or interleukin 1β synthesis or release inhibitor for treatment of type 2 diabetes or metabolic syndrome)
RN 354810-80-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 354810-83-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA

INDEX NAME)



RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 354810-88-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



RN 354810-95-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 354811-01-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)



RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)



RN 354811-07-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-08-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)



RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 354811-14-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 354811-15-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-19-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 354811-27-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 354811-28-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-29-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)- (CA INDEX NAME)



RN 354811-30-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (CA INDEX NAME)



RN 354811-31-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-32-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-33-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-34-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-35-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-36-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-37-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 354811-38-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-39-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-40-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-41-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 354811-42-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 354811-48-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-49-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-50-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-52-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (CA INDEX NAME)



RN 354811-54-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 354811-56-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (CA INDEX NAME)



RN 354811-58-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)- (CA INDEX NAME)



RN 354811-59-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 354811-60-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)- (CA INDEX NAME)



RN 354811-66-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



RN 354811-68-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 354811-82-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-83-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 918475-53-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)



L10 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:56134 CAPLUS Full-text
DN 147:163639
TI Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
AU Birrell, M. A.; McCluskie, K.; Hardaker, E.; Knowles, R.; Belvisi, M. G.
CS Respiratory Pharmacology, Imperial College London, Faculty of Medicine, National Heart and Lung Institute, London, UK
SO European Respiratory Journal (2006), 28(6), 1236-1244
CODEN: ERJOEI; ISSN: 0903-1936
PB European Respiratory Society
DT Journal
LA English
AB There is a great deal of interest in developing less invasive markers for monitoring airway inflammation and the effect of possible novel anti-inflammatory therapies that may take time to impact on disease pathol. Exhaled nitric oxide (eNO) has been shown to be a reproducible, noninvasive indicator of the inflammatory status of the airway in the clinic. The aim of the present study was to determine the usefulness of measuring eNO as a marker

of the anti-inflammatory impact of glucocorticoid and an inhibitor of κB kinase-2 (IKK-2) inhibitor 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), in a pre-clin. model of airway inflammation. Rats were given vehicle, budesonide or TPCA-1 prior to exposure to lipopolysaccharide, previously shown to induce an increase in eNO and airway neutrophilia/eosinophilia. Comparison of the effect of the two compds. on inflammatory components demonstrated a significant correlation between the impact on eNO and inflammatory cell burden in the airway. The current study demonstrates the usefulness of profiling potential disease-modifying therapies on exhaled nitric oxide levels and the way in which an effect on this noninvasive biomarker relates to effects on pathol. parameters such as lung cellularity. Information from studies such as the current one would suggest that the measurement of exhaled nitric oxide has potential for monitoring inflammatory status in lung tissue.
IT 507475-17-4, TPCA-1
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exhaled nitric oxide as noninvasive biomarker of airway inflammation in a rat model)
RN 507475-17-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1157366 CAPLUS Full-text
DN 145:465677
TI BAFF and APRIL neutralization-based methods for treating disease by regulating chronic lymphocytic leukemia (CLL) cell survival
IN Kipps, Thomas J.; Endo, Tomoyuki; Nishio, Mitsufumi
PA The Regents of the University of California, USA
SO PCT Int. Appl., 52pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006116366	A2	20061102	WO 2006-US15572	20060424
WO 2006116366	A3	20070405		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,

VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2005-674239P P 20050422

AB The invention discloses methods for regulating apoptosis in a cell comprising contacting the cell with an agent capable of neutralizing BAFF or APRIL. The invention also discloses a method for treating leukemia. The invention further discloses a method for detecting inhibitors of CLL.

IT 507475-17-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(BAFF and APRIL neutralization-based methods for treating disease by regulating chronic lymphocytic leukemia cell survival)

RN 507475-17-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:551763 CAPLUS Full-text
DN 145:180624
TI IκB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic
AU Birrell, Mark A.; Wong, Sissie; Hardaker, Elizabeth L.; Catley, Matthew C.; McCluskie, Kerryn; Collins, Michael; Haj-Yahia, Saleem; Belvisi, Maria G.
CS Respiratory Pharmacology Group, Airway Diseases Department, Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, UK
SO Molecular Pharmacology (2006), 69(6), 1791-1800
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English

AB Nuclear factor κB (NF-κB) is a transcription factor believed to be central in the expression of numerous inflammatory genes and the pathogenesis of many respiratory diseases. We have previously demonstrated increased NF-κB pathway activation in a steroid-sensitive animal model of lipopolysaccharide (LPS)-driven airway inflammation. It is noteworthy that this phenomenon was not observed in a steroid-insensitive model of elastase-induced inflammation in the rat. The aim of this study was to gather further evidence to suggest that these similar profiles of neutrophilic inflammation can be NF-κB-dependent or -independent by determining the impact of an IκB kinase-2 (IKK-2) inhibitor, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3- thiophenecarboxamide (TPCA-1). In the LPS model, TPCA-1 blocked the increase in NF-κB DNA binding, a marker

of NF-κB pathway activation. This inhibition was associated with a reduction in inflammatory mediator release [tumor necrosis factor α (TNF-α)/interleukin-1β (IL-1β)/matrix metalloproteinase-9 (MMP-9)] and lung inflammatory cell burden (neutrophilia/eosinophilia). These data were paralleled with a steroid and in human cell based assays. In the elastase-driven inflammation model, in which our group has previously failed to measure an increase in NF-κB DNA binding, neither TPCA-1 nor the steroid, affected mediator release (IL-1β/MMP-9) or cellular burden (neutrophilia/lymphomononuclear cells). This is the first study to examine the effect of an IKK-2 inhibitor in well validated models that mimic aspects of the inflammatory lesion evident in diseases such as COPD. In conclusion, we have demonstrated that animal models with similar profiles of airway inflammation can be IKK-2 inhibitor/steroid-sensitive or -insensitive. If both profiles of inflammation exist in the clinic, then this finding is extremely exciting and may lead to greater understanding of disease pathol. and the discovery of novel anti-inflammatory targets.

IT 507475-17-4, TPCA 1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(IκB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic)

RN 507475-17-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:357148 CAPLUS Full-text
DN 145:39831
TI Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β: Part I: Hit-to-Lead Strategies
AU Morwick, Tina; Berry, Angela; Brickwood, Janice; Cardozo, Mario; Catron, Katrina; DeTuri, Molly; Emeigh, Jonathan; Homon, Carol; Hrapchak, Matt; Jacober, Stephen; Jakes, Scott; Kaplita, Paul; Kelly, Terence A.; Ksiazek, John; Liuzzi, Michel; Magolda, Ronald; Mao, Can; Marshall, Daniel; McNeil, Daniel; Prokopowicz, Anthony, III; Sarko, Christopher; Scouten, Erika; Sledziona, Cynthia; Sun, Sanxing; Watrous, Jane; Wu, Jiang Ping; Cywin, Charles L.
CS Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 06801-0368, USA
SO Journal of Medicinal Chemistry (2006), 49(10), 2898-2908
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 145:39831

AB High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large nos. of active compds. are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of IκB kinase-β (IKKβ), a key regulatory enzyme in the nuclear factor-κB (NF-κB) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering addnl. opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

IT 718620-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thienopyridine class of inhibitors of IκB kinase-β: hit-to-lead strategies)

RN 718620-78-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



IT 354810-80-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thienopyridine class of inhibitors of IκB kinase-β: hit-to-lead strategies)

RN 354810-80-3 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:777848 CAPLUS Full-text
DN 145:262418
TI A Critical Assessment of Docking Programs and Scoring Functions

AU Warren, Gregory L.; Andrews, C. Webster; Capelli, Anna-Maria; Clarke, Brian; LaLonde, Judith; Lambert, Millard H.; Lindvall, Mika; Nevins, Neysa; Semus, Simon F.; Senger, Stefan; Tedesco, Giovanna; Wall, Ian D.; Woolven, James M.; Peishoff, Catherine E.; Head, Martha S.
CS GlaxoSmithKline Pharmaceuticals, Collegeville, PA, 19426, USA
SO Journal of Medicinal Chemistry (2006), 49(20), 5912-5931
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English

AB Docking is a computational technique that samples conformations of small mols. in protein binding sites; scoring functions are used to assess which of these conformations best complements the protein binding site. An evaluation of 10 docking programs and 37 scoring functions was conducted against eight proteins of seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization. All of the docking programs were able to generate ligand conformations similar to crystallog. determined protein/ligand complex structures for at least one of the targets. However, scoring functions were less successful at distinguishing the crystallog. conformation from the set of docked poses. Docking programs identified active compds. from a pharmaceutically relevant pool of decoy compds.; however, no single program performed well for all of the targets. For prediction of compound affinity, none of the docking programs or scoring functions made a useful prediction of ligand binding affinity.

IT 507475-23-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(critical assessment of docking programs and scoring functions)

RN 507475-23-2 CAPLUS

CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:638873 CAPLUS Full-text
DN 143:153276
TI Preparation of substituted heterocycles, particularly ureidothiophenes, as CHK1 kinase inhibitors for treating neoplasm
IN Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janetka, James; Lyne, Paul; Su, Mei; Toader, Doriti; Yu, Dingwei; Yu, Yan
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066163	A2	20050721	WO 2004-GB5400	20041224
	WO 2005066163	A3	20050901		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004312193	A1	20050721	AU 2004-312193	20041224
	CA 2552050	A1	20050721	CA 2004-2552050	20041224
	EP 1732920	A2	20061220	EP 2004-806196	20041224
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1922172	A	20070228	CN 2004-80042170	20041224
	BR 2004018351	A	20070508	BR 2004-18351	20041224
	JP 2007517843	T	20070705	JP 2006-548370	20041224
	US 2007010556	A1	20070111	US 2006-596930	20060629
	NO 2006003449	A	20060727	NO 2006-3449	20060726
	IN 2006MN00910	A	20070713	IN 2006-MN910	20060731
PRAI	US 2004-534310P	P	20040105		
	US 2004-553305P	P	20040315		
	WO 2004-GB5400	W	20041224		

OS MARPAT 143:153276

GI



I



II

AB Title compds. I (wherein X = NH, S, O; Y = CH, N; R1 = CN, (un)substituted alk(en)yl, alkoxy, aryl, etc.; R2, R3 = independently CONH2 and derivs., SO2NH2 and derivs., NHCONHR4; R4 = H, OH, benzyl, etc.; and their pharmaceutically acceptable salts; provided that when X = S; Y = CH; R2 = CONH2 and derivs.; and R3 = NHCONHR4; then R1 cannot be hydroxyphenyl or alkoxyphenyl; with the exception of certain compds.] were prepared as

checkpoint kinase 1 inhibitors for treating cancer. For example, a 7-step synthesis of ureidothiophene salt II•HCl, starting from phenylacetaldehyde and cyanomethyl acetate, is given. I had IC50 or EC50 ≤ 100 μM in one or both, checkpoint kinase 1 and abrogation assays.

IT 860351-93-5P, (R)-2-Amino-3-[[(5-phenyl-3-ureidothien-2-yl)carbonyl]amino]propionic acid methyl ester 860351-94-6P, 5-Phenyl-3-ureidothiophene-2-carboxylic acid ((2R)-2-amino-3-hydroxypropyl)amide 860351-95-7P, 5-Phenyl-3-ureidothiophene-2-carboxylic acid ((2S)-2-amino-3-hydroxypropyl)amide 860352-67-9P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-aminoethyl)amide 860353-74-8P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-dimethylaminoethyl)amide 860353-89-5P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid (2-hydroxyethyl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of ureidothiophenes as CHK1 kinase inhibitors for treating neoplasm)

RN 860351-93-5 CAPLUS

CN D-Alanine, 3-[[[3-[(aminocarbonyl)amino]-5-phenyl-2-thienyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 860351-94-6 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-[(2R)-2-amino-3-hydroxypropyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 860351-95-7 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-[(2S)-2-amino-3-hydroxypropyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 860353-67-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-phenyl- (CA INDEX NAME)



RN 860353-74-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(dimethylamino)ethyl]-5-phenyl- (CA INDEX NAME)



RN 860353-89-5 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-phenyl- (CA INDEX NAME)



L10 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:158658 CAPLUS Full-text

DN 142:261391

TI Preparation of thiophene compounds as CHK1 inhibitors

IN Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janetka, James; Lyne, Paul; Oza, Vibha; Springer, Stephanie; Su, Mei; Yu, Dingwei

PA Astrazeneca AB, Med.; Astrazeneca UK Limited

SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016909	A1	20050224	WO 2004-GB3473	20040812
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004265140	A1	20050224	AU 2004-265140	20040812
	CA 2535652	A1	20050224	CA 2004-2535652	20040812
	EP 1660474	A1	20060531	EP 2004-768043	20040812
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004013585	A	20061017	BR 2004-13585	20040812
	CN 1867557	A	20061122	CN 2004-80030364	20040812
	JP 2007502308	T	20070208	JP 2006-523673	20040812
	IN 2006DN00703	A	20070824	IN 2006-DN703	20060213
	NO 2006000718	A	20060301	NO 2006-718	20060214
	US 2006281666	A1	20061214	US 2006-568380	20060214
	MX 2006PA01775	A	20060517	MX 2006-PA1775	20060215
PRAI	US 2003-495580P	P	20030815		
	US 2004-576416P	P	20040528		
	WO 2004-GB3473	W	20040812		

OS CASREACT 142:261391; MARPAT 142:261391

GI





AB Title compds. I [R1, R2 = H, (un)substituted alkyl, (un)substituted heterocyclyl; with proviso that R1 and R2 are not both H; or R1 and R2 and the N to which they are attached in combination form an optionally substituted heterocyclyl; R4 = H, OH, (un)substituted carbocyclyl, etc., R5 = H, (un)substituted carbocyclyl, (un)substituted alkyl] and their pharmaceutically acceptable salts were prepared For example, amidation of compound II with (CH3)2Al-3-BOC-(S)-3-aminopiperidine, e.g., in-situ prepared by reaction of (S)-3-aminopiperidine-1-carboxylic acid tert-Bu ester with (CH3)3Al, followed by acidic deprotection afforded compound I [NR1R2 = (S)-piperidin-3-ylamino; R4 = H; OR5 = 4-MeO]·HCl in 57% overall yield. In CHK 1 (checkpoint kinase 1) inhibition assays, the IC50 value of compound I [NR1R2 = piperidin-3-ylamino; R4 = H; OR5 = 4-Et2NCH2CH2O]·CF3CO2H was 10 nM. Compds. I are claimed useful for the treatment of cancer, infection.

IT 845597-80-1P 845887-99-2P 845888-00-8P
845888-22-4P 845888-36-0P 845888-40-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophene compds. as CHK1 inhibitors for treatment of cancer, infection)

RN 845887-80-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-aminoethyl)-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 845887-99-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-

(dimethylamino)ethyl]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 845888-00-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-[2-(diethylamino)ethyl]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 845888-22-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-hydroxyethyl)-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 845888-36-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-(3-methoxypropyl)- (CA INDEX NAME)



RN 845888-40-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-(2-methoxyethyl)-5-(4-methoxyphenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:101587 CAPLUS Full-text
DN 142:329317
TI Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced t cell proliferation
AU Podolin, Patricia L.; Callahan, James F.; Bolognese, Brian J.; Li, Yue H.; Carlson, Karey; Davis, T. Gregg; Mellor, Geoff W.; Evans, Christopher; Roshak, Amy K.
CS Respiratory and Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (2005), 312(1), 373-381
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB Demonstration that IκB kinase 2 (IKK-2) plays a pivotal role in the nuclear factor-κB-regulated production of proinflammatory mols. by stimuli such as tumor necrosis factor (TNF)-α and interleukin (IL)-1 suggests that inhibition of IKK-2 may be beneficial in the treatment of rheumatoid arthritis. In the present study, we demonstrate that a novel, potent (IC50 = 17.9 nM), and selective inhibitor of human IKK-2, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), inhibits lipopolysaccharide-induced human monocyte production of TNF-α, IL-6, and IL-8 with an IC50 = 170 to 320 nM. Prophylactic administration of TPCA-1 at 3, 10, or 20 mg/kg, i.p., b.i.d., resulted in a dose-dependent reduction in the severity of murine collagen-induced arthritis (CIA). The significantly reduced disease severity and delay of disease onset resulting from administration of TPCA-1 at 10 mg/kg, i.p., b.i.d. were comparable to the effects of the antirheumatic drug, etanercept, when administered prophylactically at 4 mg/kg, i.p., every other day. Nuclear localization of p65, as well as levels of IL-1β, IL-6, TNF-α, and interferon-γ, were significantly reduced in the paw tissue of TPCA-1- and etanercept-treated mice. In addition, administration of TPCA-1 in vivo resulted in significantly decreased collagen-induced T cell proliferation ex vivo. Therapeutic administration of TPCA-1 at 20 mg/kg, but not at 3 or 10 mg/kg, i.p., b.i.d., significantly reduced the severity of CIA, as did etanercept administration at 12.5 mg/kg, i.p., every other day. These results

suggest that reduction of proinflammatory mediators and inhibition of antigen-induced T cell proliferation are mechanisms underlying the attenuation of CIA by the IKK-2 inhibitor, TPCA-1.

IT 507475-17-4
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiarthritic activity of small mol. inhibitor of IκB kinase 2, TPCA-1, via reduction of proinflammatory cytokines and antigen-induced T cell proliferation)

RN 507475-17-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:606462 CAPLUS Full-text
DN 141:157027
TI Preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.
IN Faull, Alan Wellington; Johnstone, Craig; Morley, Andrew David; Poyser, Jeffrey Philip
PA Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004063186	A1	20040729	WO 2004-GB96	20040113
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	EP 1583755	A1	20051012	EP 2004-701627	20040113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006516273	T	20060629	JP 2006-500200	20040113
	US 2006058522	A1	20060316	US 2005-542326	20050713
PRAI	SE 2003-92	A	20030115		
	WO 2004-GB96	W	20040113		

OS MARPAT 141:157027
GI



I II

III

AB Title compds. I [R1 = H, CH3; R2 = H, halo, CN, etc.; R3, R4 = H, CH3; A = 6-membered aromatic ring optionally incorporating one or two nitrogen atoms; X = NR6; R5 = H, Cl, alkyl, etc.; R6 = H, Cl, alkyl] and their pharmaceutically acceptable salts were prepared For example, Pd mediated coupling of 2-[(aminocarbonyl)amino]-5-bromothiophene-3-carboxamide and bromide II, e.g., prepared from 4-bromobenzylbromide and 2,2,2-trifluoroethylamine, afforded thiophenylcarboxamide III. In IKK-2 filter kinase inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.00056-0.066 μM, e.g., the IC50 value of thiophenylcarboxamide III was 0.0036 μM. Compds. I are claimed useful for the treatment of inflammatory diseases.

IT 728947-61-3P 728947-62-4P 728947-63-5P
728947-64-6P 728947-65-7P 728947-66-8P
728947-67-9P 728947-69-1P 728947-71-5P
728947-72-6P 728947-81-7P 728947-83-9P
728947-84-0P 728947-91-0P 728947-93-2P
728947-95-4P 728947-98-7P 728948-03-6P
728948-04-7P 728948-05-8P 728948-07-0P
728948-12-7P 728948-13-8P 728948-17-2P
728948-18-3P 728948-19-4P 728948-20-7P
728948-22-9P 728963-24-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment of inflammatory diseases.)

RN 728947-61-3 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2,2,2-trifluoroethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-62-4 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-63-5 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[bis(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-64-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[ethyl(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-65-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)



RN 728947-66-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-methoxyethyl)(2,2,2-trifluoroethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-67-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-69-1 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(methylamino)methyl]phenyl]- (CA INDEX NAME)



RN 728947-71-5 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2R)-2-

hydroxypropyl]amino]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 728947-72-6 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[[(2S)-2-hydroxypropyl]amino]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 728947-81-7 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-83-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-methoxy-1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-84-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-hydroxy-1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-91-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(5-cyanopentyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728947-93-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-methylpropyl)amino]methyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 728947-92-0
CMF C17 H22 N4 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 728947-97-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-hydroxyethyl)amino]methyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 728947-96-4
CMF C15 H18 N4 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 728947-98-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-methoxy-2-methylpropyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-03-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[ethyl(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-04-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[(2-methoxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-06-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[(2-cyanoethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-07-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[(2-methoxyethyl)(1-methylethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-12-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-13-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[(2-methoxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-17-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[[(2-methoxy-2-methylpropyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-18-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(3-methoxypropyl)amino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-19-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[(diethylamino)methyl]phenyl]- (CA INDEX NAME)



RN 728948-20-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-cyanoethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-22-9 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[(2-hydroxyethyl)methylamino]methyl]phenyl]- (CA INDEX NAME)



RN 728948-24-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[[bis(2-hydroxyethyl)amino]methyl]phenyl]- (CA INDEX NAME)



IT 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide 728948-31-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophenylcarboxamides as IKK-2 inhibitors for the treatment
of inflammatory diseases.)

RN 494773-25-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



RN 728948-31-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



L10 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:362566 CAPLUS Full-text
DN 141:99000
TI Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors
AU Baxter, Andrew; Brough, Steve; Cooper, Anne; Floettmann, Eike; Foster, Steve; Harding, Christine; Kettle, Jason; McInally, Tom; Martin, Craig; Mobbs, Michelle; Needham, Maurice; Newham, Pete; Paine, Stuart; St-Gallay, Steve; Salter, Sylvia; Unitt, John; Xue, Yafang
CS AstraZeneca R&D Charnwood, Loughborough, LE11 5RH, UK
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(11), 2817-2822
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
GI



I

AB A hit-to-lead optimization program was carried out on the thiophenecarboxamide high throughput screening hits 1 and 2 resulting in the discovery of the potent and orally bioavailable IKK-2 inhibitor (I).

IT 354810-83-6 354810-95-0 354811-01-1
354811-04-4 354811-06-6 354811-09-9
354811-10-2 718620-76-9 718620-77-0
718620-78-1 718620-79-2 718620-81-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)

RN 354810-83-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)



RN 354810-95-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 354811-01-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)



RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA INDEX NAME)



RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)



RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 718620-76-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N-methyl-5-phenyl- (CA INDEX NAME)



RN 718620-77-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-N,N-dimethyl-5-phenyl- (CA INDEX NAME)



RN 718620-78-1 CAPLUS

CN 2-Thiophenecarboxamide, 3-[[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



RN 718620-79-2 CAPLUS
CN 2-Thiophenecarboxamide, 3-[[(ethylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



RN 718620-81-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[[(dimethylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



IT 354810-80-3
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)
RN 354810-80-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



IT 354810-86-9
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high throughput screening of potent, orally active, thiophenecarboxamide IKK-2 inhibitors)
RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:282559 CAPLUS Full-text
DN 138:304153
TI Preparation of 2-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders
IN Parrish, Cynthia A.; Callahan, James F.; Li, Yue; Stavenger, Robert A.; Holt, Dennis A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003029241	A1	20030410	WO 2002-US31752	20021004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002340102	A1	20030414	AU 2002-340102	20021004
PRAI US 2001-326977P	P	20011004		
WO 2002-US31752	W	20021004		

OS MARPAT 138:304153
GI



AB Ureidothiophenes (shown as I; variables defined below; e.g. 5-(4-fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide) useful in the inhibition of angiogenesis and damage response kinases (no data) are provided. Although the methods of preparation are not claimed, 46 example prepns. are included. For I: R1 = H, C1-2 alkyl, XH, XCH3, C1-2-alkyl-XH, C1-2 alkyl-XCH3, C(O)NH2, C(O)NHCH3, and C(O)-C1-2-alkyl; X = O, S, and NH; R2 = C(O)R5, CO2R5, C(O)NHR5, C(O)NHC(:NH)R5, C(O)NHC(:NH)NR5R6, C(O)NHC(O)R5, C(O)NHC(O)NR5R6, SO2R5, S(O)R5, SO3R5, and PO3R5R6. R3 is H or halogen; R4 is aryl or heteroaryl; addnl. details are given in the claims.
IT 106666-24-6P, 2-(3-Methylureido)-5-phenylthiophene-3-carboxylic acid amide 354811-10-2P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid amide 354811-59-9P, 5-(4-Trifluoromethylphenyl)-2-ureidothiophene-3-carboxylic acid amide 354811-67-9P, 5-(4-Chlorophenyl)-2-ureidothiophene-3-carboxylic acid amide 354811-68-0P, 5-(4-Methanesulfonylphenyl)-2-ureidothiophene-3-carboxylic acid amide 354812-11-6P, 5-(4-Methoxyphenyl)-2-ureidothiophene-3-carboxylic acid amide 412914-36-4P, 5-(3-Chlorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 412914-37-5P, 5-(4-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 412914-52-4P, 2-(3-Ethylureido)-5-phenylthiophene-3-carboxylic acid amide 412914-54-6P, 5-(2-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 412914-57-9P, 2-(3-Methylureido)-5-p-tolylthiophene-3-carboxylic acid amide 412914-58-0P, 5-(3-Chloro-4-fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-17-4P, 5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-20-9P, 5-p-Tolyl-2-ureidothiophene-3-carboxylic acid amide 507475-21-0P, 5-(4-Chlorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-23-2P, 5-(4-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-24-3P, 5-(4-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid methylamide 507475-25-4P, 2-(3-Methylureido)-5-phenylthiophene-3-carboxylic acid methylamide 507475-26-5P, 5-Phenyl-2-ureidothiophene-3-carboxylic acid methylamide 507475-29-8P, 5-(2-Fluorophenyl)-2-ureidothiophene-3-carboxylic acid amide 507475-35-6P, 5-(4-Methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-37-8P, 5-(4-Cyanophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-38-9P, 5-(4-Dimethylaminophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-39-0P, 5-(4-Hydroxymethylphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-40-3P, 5-(3-Fluorophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-41-4P, 5-(3-Aminophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-43-6P, 5-(4-Aminophenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-44-7P, 5-(3-Hydroxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-46-9P, 5-(3-Acetylphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid amide 507475-50-5P, 2-(3-Methylureido)-5-(3-trifluoromethylphenyl)thiophene-3-carboxylic acid methylamide 507475-51-6P, 5-(4-Methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid methylamide 507475-52-7P, 5-(4-Aminophenyl)-2-(3-

methylureido)thiophene-3-carboxylic acid methylamide 507475-53-8P
, 5-(4-Hydroxy-3-methoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic
acid methylamide 507475-54-9P, 5-(4-Hydroxymethylphenyl)-2-(3-
methylureido)thiophene-3-carboxylic acid methylamide 507475-55-0P
, 5-(3,4-Dimethoxyphenyl)-2-(3-methylureido)thiophene-3-carboxylic acid
methylamide 507475-56-1P, 5-(3-Fluorophenyl)-2-ureidothiophene-3-
carboxylic acid amide 507475-57-2P, 5-(3-Cyanophenyl)-2-
ureidothiophene-3-carboxylic acid amide 507475-58-3P,
5-(4-Ethylphenyl)-2-ureidothiophene-3-carboxylic acid amide
507475-59-4P, 5-(3-Methoxyphenyl)-2-ureidothiophene-3-carboxylic
acid amide 507475-60-7P, 5-(3-Hydroxymethylphenyl)-2-
ureidothiophene-3-carboxylic acid amide 507475-61-8P,
5-(3,4-Dichlorophenyl)-2-ureidothiophene-3-carboxylic acid amide
507475-62-9P, 5-(3-Trifluoromethylphenyl)-2-ureidothiophene-3-
carboxylic acid amide 507475-63-0P, 5-(3,4-Difluorophenyl)-2-
ureidothiophene-3-carboxylic acid amide 507475-64-1P,
[5-Phenyl-3-(1-ureidomethanoyl)thiophen-2-yl]urea 507475-65-2P,
1-Methyl-3-[5-phenyl-3-(1-ureidomethanoyl)thiophen-2-yl]urea
507475-67-4P, [5-(4-Fluorophenyl)-3-(1-ureidomethanoyl)thiophen-2-
yl]urea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of 2-ureidothiophenes as angiogenesis and Chk1
kinase inhibitors for treating various forms of cancer and
hyperproliferative disorders)

RN 106666-34-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(methylamino)carbonyl]amino]-5-phenyl- (9CI)
(CA INDEX NAME)



RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX
NAME)



RN 354811-59-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 354811-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA
INDEX NAME)



RN 354811-68-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-
(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 354812-11-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA
INDEX NAME)



RN 412914-36-4 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-chlorophenyl)-2-[[(methylamino)carbonyl]amino
]- (CA INDEX NAME)



RN 412914-37-5 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-2-[[(methylamino)carbonyl]amino
]- (CA INDEX NAME)



RN 412914-52-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(ethylamino)carbonyl]amino]-5-phenyl- (CA
INDEX NAME)



RN 412914-54-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(2-fluorophenyl)-2-[[(methylamino)carbonyl]amino
]- (CA INDEX NAME)



RN 412914-57-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(methylamino)carbonyl]amino]-5-(4-
methylphenyl)- (CA INDEX NAME)



RN 412914-58-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-
fluorophenyl)- (CA INDEX NAME)



RN 507475-17-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA
INDEX NAME)



RN 507475-20-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methylphenyl)- (CA
INDEX NAME)



RN 507475-21-0 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-chlorophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-23-2 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-24-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 507475-25-4 CAPLUS
CN 3-Thiophenecarboxamide, N-methyl-2-[[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



RN 507475-26-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-N-methyl-5-phenyl- (CA INDEX NAME)



RN 507475-29-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-fluorophenyl)- (CA INDEX NAME)



RN 507475-35-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-37-8 CAPLUS

CN 3-Thiophenecarboxamide, 5-(4-cyanophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-38-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-[4-(dimethylamino)phenyl]-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-39-0 CAPLUS
CN 3-Thiophenecarboxamide, 5-[4-(hydroxymethyl)phenyl]-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-40-3 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-fluorophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-41-4 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-aminophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-43-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-aminophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-44-7 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-hydroxyphenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-46-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-acetylphenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-50-5 CAPLUS
CN 3-Thiophenecarboxamide, N-methyl-2-[[(methylamino)carbonyl]amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 507475-51-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-52-7 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-aminophenyl)-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-53-8 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-hydroxy-3-methoxyphenyl)-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-54-9 CAPLUS
CN 3-Thiophenecarboxamide, 5-[4-(hydroxymethyl)phenyl]-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-55-0 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507475-56-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)- (CA INDEX NAME)



RN 507475-57-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-cyanophenyl)- (CA INDEX NAME)



RN 507475-58-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-ethylphenyl)- (CA INDEX NAME)



RN 507475-59-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)



RN 507475-60-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-(hydroxymethyl)phenyl]- (CA INDEX NAME)



RN 507475-61-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)- (CA INDEX NAME)



RN 507475-62-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 507475-63-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-difluorophenyl)- (CA INDEX NAME)



RN 507475-64-1 CAPLUS
CN 3-Thiophenecarboxamide, N-(aminocarbonyl)-2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 507475-65-2 CAPLUS
CN 3-Thiophenecarboxamide, N-(aminocarbonyl)-2-[[(methylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



RN 507475-67-4 CAPLUS
CN 3-Thiophenecarboxamide, N-(aminocarbonyl)-2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:282401 CAPLUS Full-text
DN 138:304152
TI Preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders
IN Parrish, Cynthia A.; Callahan, James F.; Wan, Zehong; Burgess, Joelle L.; Stavenger, Robert A.; Holt, Dennis A.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2003028731 A1 20030410 WO 2002-US31901 20021004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002330247 A1 20030414 AU 2002-330247 20021004
PRAI US 2001-326971P P 20011004
WO 2002-US31901 W 20021004
OS MARPAT 138:304152
GI



AB Ureidothiophenes (shown as I; variables defined below; e.g. 5-phenyl-3-ureidothiophene-2-carboxylic acid Me ester) useful in the inhibition of angiogenesis and damage response kinases (no data) are provided. Although the methods of preparation are not claimed, 36 example prepns. are included. For I: R1 = H, C1-2 alkyl, XH, XCH3, C1-2-alkyl-XH, C1-2 alkyl-XCH3, C(O)NH2, C(O)NHCH3, and C(O)-C1-2-alkyl; X = O, S, and NH; R2 = C(O)R5, CO2R5, C(O)NHR5, C(O)NHC(:NH)R5, C(O)NHC(:NH)NR5R6, C(O)NHC(O)R5, C(O)NHC(O)NR5R6, SO2R5, S(O)R5, SO3R5, and PO3R5R6. R3 is H or halogen; R4 is aryl or heteroaryl; addnl. details are given in the claims.
IT 354810-86-9P, 5-(4-Fluorophenyl)-3-ureidothiophene-2-carboxylic acid amide 354810-95-0P, 5-(4-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid amide 507472-56-2P, 5-(4-Methoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid amide 507472-64-2P, 5-(4-Methoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide 507472-66-4P, 5-(4-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid methylamide 507472-67-5P, 5-(3,4-Dimethoxyphenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide 507472-71-1P, 5-(4-Aminophenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)
RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



2X Sr not in generic

RN 354810-95-0 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 507472-56-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-(4-methoxyphenyl)-3-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507472-64-2 CAPLUS
CN 2-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-methyl-3-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507472-66-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-N-methyl- (CA INDEX NAME)



RN 507472-67-5 CAPLUS
CN 2-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-methyl-3-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 507472-71-1 CAPLUS
CN 2-Thiophenecarboxamide, 5-(4-aminophenyl)-N-methyl-3-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



IT 507472-73-3P, 5-(4-Nitrophenyl)-3-(3-methylureido)thiophene-2-carboxylic acid methylamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-ureidothiophenes as angiogenesis and Chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders)
RN 507472-73-3 CAPLUS
CN 2-Thiophenecarboxamide, N-methyl-3-[[(methylamino)carbonyl]amino]-5-(4-nitrophenyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:97411 CAPLUS Full-text
DN 138:137162
TI Preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase
IN Faull, Alan; Johnstone, Craig; Morley, Andrew; Poyser, Jeffrey Philip
PA Astrazeneca A.B., Swed.
SO PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003010158	A1	20030206	WO 2002-SE1403	20020719
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2454703	A1	20030206	CA 2002-2454703	20020719
	AU 2002355245	A1	20030217	AU 2002-355245	20020719
	EP 1421074	A1	20040526	EP 2002-751935	20020719
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011473	A	20041026	BR 2002-11473	20020719
	CN 1541214	A	20041027	CN 2002-815836	20020719
	JP 2005503372	T	20050203	JP 2003-515517	20020719
	NZ 530750	A	20050826	NZ 2002-530750	20020719
	US 2004242573	A1	20041202	US 2004-484569	20040122
	US 7125896	B2	20061024		
	ZA 2004000492	A	20050422	ZA 2004-492	20040122
	NO 2004000313	A	20040325	NO 2004-313	20040123
	MX 2004PA00756	A	20040420	MX 2004-PA756	20040123
	HK 1071129	A1	20061229	HK 2005-103629	20050427
	US 2007015819	A1	20070118	US 2006-516225	20060906
PRAI	SE 2001-2616	A	20010725		
	WO 2002-SE1403	W	20020719		
	US 2004-484569	A3	20040122		

OS MARPAT 138:137162
GI



I



II

AB Title compds. I (R1 = NH2, (un)substituted methyl; X = O, S; R2 = H, halo, CN, NO2, amino, carboxamido, carboxy, etc.; A = Ph, 5-7-membered (un)substituted heteroarom. ring; n = 1-2; R3 = W-Y-Z; W = O, SO0-2; amino, CH2(O), bond; Y = (CH2)0-2-T-(CH2)0-2; T = O, CO, alkyl; Z = Ph, 5-6-membered (un)substituted heteroarom. ring, etc.; with specific exceptions] are prepared For instance, (1,1'-biphenyl-4-yl)acetone, cyanoacetamide, sulfur and morpholine in EtOH at 55° are reacted to give 2-Amino-4-methyl-5-(1,1'-biphenyl-4-yl)-3-thiophencarboxamide. This intermediate is treated with trichloroacetyl isocyanate and ammonia in MeOH to give example compound II. Compds. of the invention have IC50 < 10 μM for IKK2 kinase. I are useful for the treatment of inflammatory diseases.

IT 494772-63-3P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-74-6P, 2-[(Aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]-3-thiophenecarboxamide 494772-76-8P, 2-[(Aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-3-thiophenecarboxamide 494772-59-0P, 2-[(Aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]thiophene-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)

RN 494772-63-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (CA INDEX NAME)



RN 494772-74-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(2-methoxyethoxy)ethoxy]-3-methylphenyl]- (CA INDEX NAME)



RN 494772-76-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[3-chloro-4-[2-(2-methoxyethoxy)ethoxy]phenyl]- (CA INDEX NAME)



RN 494773-59-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[2-(2-hydroxyethoxy)phenyl]- (CA INDEX NAME)



IT 494772-79-1P, 2-[(Aminocarbonyl)amino]-5-(2-formylphenyl)-3-thiophenecarboxamide 494773-25-0P, 2-[(Aminocarbonyl)amino]-5-(4-formylphenyl)thiophene-3-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase)

RN 494772-79-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-formylphenyl)- (CA INDEX NAME)



RN 494773-25-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-formylphenyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:293385 CAPLUS Full-text
DN 136:325411
TI Preparation of 2-aminothiophene-3-carboxamides as NF-κB inhibitors
IN Callahan, James F.; Russell, Amy K.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030353	A2	20020418	WO 2001-US31866	20011012
	WO 2002030353	A3	20020627		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002011663	A5	20020422	AU 2002-11663	20011012
	EP 1324759	A2	20030709	EP 2001-979731	20011012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004523476	T	20040805	JP 2002-533800	20011012
	US 2004024047	A1	20040205	US 2003-398106	20030410
	US 2006030596	A1	20060209	US 2005-237232	20050928

PRAI US 2000-239759P P 20001012
WO 2001-US31866 W 20011012
US 2003-398847 B1 20030410
OS MARPAT 136:325411
GI



AB The title compds. [I; R1 = NR5R6; R2 = CONH2, SO2NH2; R3 = H, halo; R4 = aryl, heteroaryl; R5 = H, alkyl; R6 = H, COalkyl, SO2alkyl, etc.], useful as inhibitors of IKK-β phosphorylation of IκB, were prepared Thus, treating (4-fluorophenyl)ethanol with PCC in CH2Cl2 followed by reacting the resulting (4-fluorophenyl)acetaldehyde with sulfur and 2-cyanoacetamide in the presence of Et3N in DMF afforded 2-amino-5-(4-fluorophenyl)thiophene-3-carboxamide.
IT 106666-34-6P 106666-36-8P 412914-36-4P
412914-37-5P 412914-52-4P 412914-54-6P
412914-57-9P 412914-58-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminothiophene-3-carboxamides as NF-κB inhibitors)
RN 106666-34-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(methylamino)carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-36-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 412914-36-4 CAPLUS
CN 3-Thiophenecarboxamide, 5-(3-chlorophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 412914-37-5 CAPLUS
CN 3-Thiophenecarboxamide, 5-(4-fluorophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 412914-52-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(ethylamino)carbonyl]amino]-5-phenyl- (CA INDEX NAME)



RN 412914-54-6 CAPLUS
CN 3-Thiophenecarboxamide, 5-(2-fluorophenyl)-2-[[(methylamino)carbonyl]amino]- (CA INDEX NAME)



RN 412914-57-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(methylamino)carbonyl]amino]-5-(4-methylphenyl)- (CA INDEX NAME)



RN 412914-58-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-fluorophenyl)- (CA INDEX NAME)



L10 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:597977 CAPLUS Full-text
DN 135:180698
TI Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2
IN Baxter, Andrew; Brough, Stephen; Faull, Alan; Johnstone, Craig; Mcinally, Thomas
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001058890	A1	20010816	WO 2001-SE248	20010207

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2396824	A1	20010816	CA 2001-2396824	20010207
EP 1261600	A1	20021204	EP 2001-902951	20010207
EP 1261600	B1	20040506		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001008143	A	20030121	BR 2001-8143	20010207
JP 2003522766	T	20030729	JP 2001-558440	20010207
AT 266019	T	20040515	AT 2001-902951	20010207
NZ 519947	A	20040528	NZ 2001-519947	20010207
PT 1261600	T	20040831	PT 2001-902951	20010207
ES 2218376	T3	20041116	ES 2001-1902951	20010207
AU 781047	B2	20050505	AU 2001-30705	20010207
US 2002107252	A1	20020808	US 2002-868884	20020205
ZA 2002005300	A	20031002	ZA 2002-5300	20020702
NO 2002003786	A	20020923	NO 2002-3786	20020809
MX 2002PA07734	A	20021011	MX 2002-PA7734	20020809
PRAI GB 2000-3154	A	20000212		
WO 2001-SE248	W	20010207		

OS MARPAT 135:180698
GI





AB The title compds. [I; A = 5-membered heteroarom. ring containing 1-2 heteroatoms selected from O, N or S; R1 = (un)substituted Ph, 5-7 membered heteroarom. ring containing 1-3 heteroatoms selected from O, N or S; R2 = H, halo, CN, etc.; X = O, S], useful in the treatment or prophylaxis of inflammatory disease, were prepared Thus, refluxing 3-amino-5-phenyl-2-thiophenecarboxamide with trimethylsilyl isocyanate in DMF/CH2Cl2 afforded II.
IT 354811-01-1P 354811-06-6P 354811-31-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)
RN 354811-01-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-06-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-methoxyphenyl)- (CA

INDEX NAME)



RN 354811-31-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)-4-methyl- (CA INDEX NAME)



IT 354810-80-3P 354810-83-6P 354810-86-9P
354810-88-1P 354810-90-5P 354810-95-0P
354811-04-4P 354811-07-7P 354811-08-8P
354811-09-9P 354811-10-2P 354811-14-6P
354811-15-7P 354811-19-1P 354811-27-1P
354811-28-2P 354811-29-3P 354811-30-6P
354811-32-8P 354811-33-9P 354811-34-0P
354811-35-1P 354811-36-2P 354811-37-3P
354811-38-4P 354811-39-5P 354811-40-8P
354811-41-9P 354811-42-0P 354811-48-6P
354811-49-7P 354811-50-0P 354811-52-2P
354811-54-4P 354811-56-6P 354811-58-8P
354811-59-9P 354811-60-2P 354811-66-8P
354811-67-9P 354811-68-0P 354811-82-9P
354811-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354810-80-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 354810-83-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-chlorophenyl)- (CA INDEX NAME)



RN 354810-86-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-fluorophenyl)- (CA INDEX NAME)



RN 354810-88-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



RN 354810-90-5 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-(2-methylpropyl)phenyl]- (CA INDEX NAME)



RN 354810-95-0 CAPLUS

CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RN 354811-04-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-chlorophenyl)- (CA INDEX NAME)



RN 354811-07-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-08-8 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-09-9 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)- (CA INDEX NAME)



RN 354811-10-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl- (CA INDEX NAME)



RN 354811-14-6 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[4-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 354811-15-7 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-19-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[3-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 354811-27-1 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-[2-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 354811-28-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-29-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(4-methylphenyl)- (CA INDEX NAME)



RN 354811-30-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-ethyl-5-phenyl- (CA INDEX NAME)



RN 354811-32-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-33-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-fluorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-34-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-35-1 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3-chloro-4-

methoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-36-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2-chlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-37-3 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 354811-38-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxy-3-methylphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-39-5 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,5-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-40-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,3-dimethoxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-41-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 354811-42-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 354811-48-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(3,4-dichlorophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-49-7 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)-4-methyl- (CA INDEX NAME)



RN 354811-50-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)-4-methyl- (CA INDEX NAME)



RN 354811-52-2 CAPLUS

CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]-4-methyl- (CA INDEX NAME)



RN 354811-54-4 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-phenyl-4-(trifluoromethyl)- (CA INDEX NAME)



RN 354811-56-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-4-methyl-5-phenyl- (CA INDEX NAME)



RN 354811-58-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-cyanophenyl)- (CA INDEX NAME)



RN 354811-59-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 354811-60-2 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(2,4-difluorophenyl)- (CA INDEX NAME)



RN 354811-66-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-67-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-chlorophenyl)- (CA INDEX NAME)



RN 354811-68-0 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 354811-82-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 354811-83-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-[4-[2-(diethylamino)ethoxy]phenyl]- (CA INDEX NAME)



IT 354811-95-3P 354811-96-4P 354812-11-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2)

RN 354811-95-3 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(2-hydroxyphenyl)- (CA INDEX NAME)



RN 354811-96-4 CAPLUS
CN 2-Thiophenecarboxamide, 3-[(aminocarbonyl)amino]-5-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 354812-11-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[(aminocarbonyl)amino]-5-(4-methoxyphenyl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:423224 CAPLUS Full-text
DN 107:23224
TI Thienylureas and -isoureas and their preparation and use as growth promoters for animals
IN Hallenbach, Werner; Lindel, Hans; Berschauer, Friedrich; Scheer, Martin; De Jong, Arno
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 79 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3529247	A1	19861120	DE 1985-3529247	19850816
	EP 202538	A1	19861126	EP 1986-106209	19860506
	EP 202538	B1	19881228		

R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE					
AT 39404	T	19890115	AT 1986-106209	19860506	
AU 8657217	A	19861120	AU 1986-57217	19860507	
JP 61268678	A	19861128	JP 1986-109713	19860515	
DK 8602300	A	19861118	DK 1986-2300	19860516	
BR 8602224	A	19870113	BR 1986-2224	19860516	
ZA 8603645	A	19870128	ZA 1986-3645	19860516	
HU 41244	A2	19870428	HU 1986-2086	19860516	
ES 555052	A1	19880216	ES 1986-555052	19860516	
CS 258481	B2	19880816	CS 1986-3569	19860516	
FI 8602201	A	19861118	FI 1986-2201	19860526	
PRAI DE 1985-3517706	A1	19850517			
DE 1985-3529247	A	19850816			
EP 1986-106209	A	19860506			

OS CASREACT 107:23224
GI



AB Title compds. I [A = NR4CONR5R6, NR4C(OR5):NR6; R1, R2 = H, halo, NO2, CN, (halo)alkoxy, (halo)alkylthio, alkoxyalkyl, (un)substituted acyl, aroyl, alkyl, aryl; R1R2 complete a(n) (un)substituted carbocyclic or heterocyclic ring, optionally with a carbonyl function; R3 = CN, CO2R7, CONR8R9, COR10; R4 = H, alkyl; R5,R6 = H, (un)substituted alkyl, cycloalkyl, alkenyl, aryl, heteroaryl; R7 = H, (un)substituted alkyl, cycloalkyl, alkenyl, aryl; R8 = H, alkyl, cycloalkyl; R9, R10 = (un)substituted alkyl or aryl], useful as growth promoters for animals, were prepared by 3 methods. 2-Aminotetrahydrobenzothiophene-3-carboxamide and MeNCO in CHCl3 were refluxed 24 h to give 95% II. Rats fed with 10 ppm II mixed in their feed gained 14% more weight than the controls.
IT 106666-34-6P 106666-36-8P 106666-50-6P
106666-51-7P 106666-52-8P 106686-20-8P
108354-55-8P 108354-56-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as animal growth promoter)
RN 106666-34-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(methylamino)carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-36-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-50-6 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[(methylamino)carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-51-7 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(2-methylpropyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-52-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(butylamino)carbonyl]amino]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 106686-20-8 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 108354-55-8 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylpropyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 108354-56-9 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:83475 CAPLUS Full-text
DN 106:83475
TI Productivity-increasing agents for livestock
IN Hallenbach, Werner; Lindel, Hans; Berschauer, Friedrich; Scheer, Martin; De Jong, Anno
PA Bayer A.-G., Fed. Rep. Ger.
SO Eur. Pat. Appl., 80 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 202538	A1	19861126	EP 1986-106209	19860506
	EP 202538	B1	19881228		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	DE 3529247	A1	19861120	DE 1985-3529247	19850816
	AT 39404	T	19890115	AT 1986-106209	19860506
PRAI	DE 1985-3517706	A	19850517		
	DE 1985-3529247	A	19850816		
	EP 1986-106209	A	19860506		

OS MARPAT 106:83475
GI

I

AB Productivity-increasing agents for livestock comprise thienylurea or thienylisourea derivs. I (A = NH2, NCO, NR4CONR5R6, NHR4, NR4C(OR5)NR6; R1, R2 = H, halogen, nitro, CN, (un)substituted alkyl, aryl, etc.; R3 = CN, COOR7, CONR8R9, COR10; R4 = H, alkyl; R5, R6 = H, substituted alkyl, cycloalkyl, alkenyl, aryl, heteroaryl; R7 = H, substituted alkyl, cycloalkyl, alkenyl, aryl; R8 = H, alkyl, cycloalkyl; R9 = H, substituted alkyl or aryl; R10 = substituted alkyl or aryl). Thus, 218 thienylurea and thienylisourea compds. were prepared N-Butyl-N'-(3- methoxycarbonyltetrahydrobenzothien-2-yl)urea, given to rats at 25 ppm. in their feed for 13 days increased weight gain by 13% over that of control rats.

IT 106666-34-6P 106666-36-8P 106666-50-6P
106666-51-7P 106666-52-8P 106686-20-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as livestock productivity-increasing agent)

RN 106666-34-6 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(methylamino)carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-36-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-50-6 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[(methylamino)carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-51-7 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(2-methylpropyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 106666-52-8 CAPLUS
CN 3-Thiophenecarboxamide, 2-[[(butylamino)carbonyl]amino]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 106686-20-8 CAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[[[(1-methylethyl)amino]carbonyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



```
=> d cost
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CONNECT CHARGES                                   0.41       2.92
NETWORK CHARGES                                   0.06       0.48
SEARCH CHARGES                                    0.00     180.62
DISPLAY CHARGES                                 108.23     108.23
                                              --------   --------
FULL ESTIMATED COST                             108.70     292.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                             -16.38     -16.38

IN FILE 'CAPLUS' AT 11:01:25 ON 20 NOV 2007


=> log hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             108.70     292.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                             -16.38     -16.38

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:01:31 ON 20 NOV 2007
```